Is AstraZeneca answering German price cuts with German job cuts?

AstraZeneca ($AZN) is joining the line-up of drugmakers cutting jobs in Germany. Like the others, AZ cites the usual economic reasons, but adds a political twist. Also to blame for up to 625 job cuts? "[M]assive state intervention in the pricing of innovative medicines," the company says. AstraZeneca has had its own internal troubles in yielding new drugs from its R&D pipeline, but external factors such as drug pricing impact the industry. Article

 

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.